Clinical Trial Update: Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tiratricol for Monocarboxylate Transporter 8 Deficiency has involved withdrawal of tiratricol treatment in male participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allan-herndon-dudley Syndrome
• Monocarboxylate Transporter Deficiency

Drugs mentioned

• tiratricol (tiratricol)

Snippet

Sponsor: Rare Thyroid Therapeutics International AB | Conditions: Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome | Phase 3 | Status: COMPLETED